CD19 and diffuse large B-cell lymphoma: In a study of 14 patients with DLBCL relapsing or progressing after loncastuximab tesirine treatment (CD19‐positive, n = 10; not checked, n = 4 after treatment failure), and subsequently undergoing CD19‐directed CAR T‐cell therapy, the best response at 3 months included six patients (43%) with a CR and one patient (7%) with a PR; the ORR was 50%.121